Formulations containing two or more than two herbs are called polyherbal formulation. single herb formulation have been well established due to their active phytoconstituents, they usually present in minute amount and sometimes they are insufficient to achieve the desirable therapeutic effects. Popularity of polyherbal formulation is due to their high effectiveness in a vast number of diseases.
Aim of the study: The main aim of this study was to evaluation of neurobehavioral and biochemical parameters of poly- herbal formulation on MPTP-intoxicated mice for the treatment of PD.
Materials and Methods: In this study there are preparing a poly-herbal formulation by using different solvent extract with the help of hot extraction process by Soxhlet Apparatus. The poly-herbal formulation has been prepared by using traditional herbal plants namely, Bacopa monereri (BM), Embelica officinalis (EO), Mucuna pruriens (MP), & Withania somnifera (WS). Different combinations of PHFs (PHF1to5) were prepared by using the extracts in different ratios. The prepared PHFs were optimized for antioxidant potential by DPPH assay. 18 Swiss albino mice (30-50 g) grouped into Control, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), MPTP+PHF1 (6 mice in each group). Experimental mice were given PHF1 (50 mg/kg body wt. by intraperitoneal route). MPTP (1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine) treatment was given orally for 2 week with prior use of 20 mg/kg body wt. for 2 week. After treatment period, Neurobehavioral study and neuroprotective effect was done via biochemical parameters.
Results: The above study was mentioned that PHF1 was upgraded the dopaminic neurons in the brain. A significant diminution were found in SLA activity in MPTP treated mice as compared to control group which was restored by MPTP+PHF1 treated group as compared to MPTP treated group.
Conclusions: The result concluded that PHF1 enhanced the dopaminic neurons in the substantia nigra region of the brain. Hence this poly-herbal formulation gives a better and novel treatment for future drug discoveries in the case of Parkinson’s disease (PD)